{"id":35843,"date":"2015-05-08T08:08:17","date_gmt":"2015-05-08T12:08:17","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=35843"},"modified":"2015-05-08T08:08:17","modified_gmt":"2015-05-08T12:08:17","slug":"abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843","title":{"rendered":"AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199)"},"content":{"rendered":"<p style=\"text-align: justify;\">In a fast paced world, <strong>AbbVie Inc (NYSE:ABBV)<\/strong> intends to take quick actions to make everything falls in line. Recently it mentioned Venetoclax (ABT-199), late stage cancer drug of the company as a strong reason due to which it wanted to acquire Imbruvica-maker Pharmacyclics for a whopping $21 billion.<\/p>\n<p style=\"text-align: justify;\">AbbVie anticipates that if blood cancer blockbuster is matched with its experimental therapy, it can easily elevate its market share and reach in the domestic and international market. <a href=\"http:\/\/www.fiercebiotech.com\/story\/abbvie-gets-breakthrough-one-its-top-cancer-drugs\/2015-05-07\">Reports<\/a> claim that FDA has taken this argument to all new heights with BTD or breakthrough therapy designation for venetoclax. Experts claim that the procedure of getting approval for this therapy will now become easy and hassle-free for the company.<\/p>\n<p style=\"text-align: justify;\"><strong>Road So Far:<\/strong><\/p>\n<p style=\"text-align: justify;\">Initially, the U.S. Food and Drug Administration handed out the bragging rights of breakthrough therapy designation for patients that have chronic lymphocytic leukemia (CLL) and suffering from 17p deletion genetic mutation. Close to 3%-10% of all the first line patients suffer from this type of mutation.<\/p>\n<p style=\"text-align: justify;\">ASH which has partnered with Roche impressed analysts in 2014 with its extra-ordinary results. During the procedure, investigators found an 88% response rate and a wide number of remissions among refractory CLL patients who took Rituxan and venetocla together.<\/p>\n<p style=\"text-align: justify;\">Venetoclax works excellent by inhibiting the protein named BCL-2, which is responsible for saving cells from dying. It makes venetoclax a natural therapy to treat such deadly disease at a time when scientists are trying to figure out optimal solutions in a cost effective way.<\/p>\n<p style=\"text-align: justify;\">Drug makers have started focusing on enhancing their investments in oncology. It&#8217;s an ideal opportunity for venetoclax to hit the market and take the standards to a new level. AbbVie Inc (NYSE:ABBV) takes it as a great opportunity and hopes that it will be able to come up with an effective solution for cancer in the near future.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a fast paced world, AbbVie Inc (NYSE:ABBV) intends to take quick actions to make everything falls in line. Recently it mentioned Venetoclax (ABT-199), late [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":21657,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1593,1592],"stock_ticker":[],"class_list":["post-35843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-abbvie-inc-nyseabbv","tag-nyseabbv","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199) - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199) - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"In a fast paced world, AbbVie Inc (NYSE:ABBV) intends to take quick actions to make everything falls in line. Recently it mentioned Venetoclax (ABT-199), late [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-08T12:08:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"456\" \/>\n\t<meta property=\"og:image:height\" content=\"190\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199)\",\"datePublished\":\"2015-05-08T12:08:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843\"},\"wordCount\":317,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"keywords\":[\"AbbVie Inc. (NYSE:ABBV)\",\"NYSE:ABBV\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843\",\"name\":\"AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"datePublished\":\"2015-05-08T12:08:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"width\":456,\"height\":190},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199) - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843","og_locale":"en_US","og_type":"article","og_title":"AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199) - Wall Street PR","og_description":"In a fast paced world, AbbVie Inc (NYSE:ABBV) intends to take quick actions to make everything falls in line. Recently it mentioned Venetoclax (ABT-199), late [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-05-08T12:08:17+00:00","og_image":[{"width":456,"height":190,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199)","datePublished":"2015-05-08T12:08:17+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843"},"wordCount":317,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","keywords":["AbbVie Inc. (NYSE:ABBV)","NYSE:ABBV"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843","url":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843","name":"AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","datePublished":"2015-05-08T12:08:17+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","width":456,"height":190},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-gets-breakthrough-for-venetoclax-abt-199-35843#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"AbbVie Inc (NYSE:ABBV) Gets Breakthrough For Venetoclax (ABT-199)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=35843"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35843\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/21657"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=35843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=35843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=35843"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=35843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}